Niek van Bree
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Niek van Bree has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Margareta Wilhelm
Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, Stockholm, Sweden
4 shared publications - Fredrik Johansson Swartling
Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
2 shared publications Johanna Wolfsberger
Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 171 65 Stockholm, Sweden
2 shared publicationsLeilei Zhou
Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet , Stockholm
2 shared publicationsMarina Stantic
Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 171 65 Stockholm, Sweden
2 shared publications- Veronica Zubillaga
Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 171 65 Stockholm, Sweden
2 shared publications
Latest Publications
- Open Access
- 31 March 2025
- Published by Karolinska Institutet
Development of translational models and identification of novel therapeutic targets for medulloblastoma
Medulloblastoma (MB), the most frequent malignant brain cancer in children, has traditionally been studied using established cell lines, patient-derived xenografts, engineered mouse models, and orthotopic transplants. While these models have been instrumental in advancing our understanding of MB pathogenesis, they predominantly represent later stages of tumor development, failing to adequately capture the early events of tumor initiation and progression. Moreover, many preclinical in vivo models are unable to fully recapitulate human tumor pathogenesis due to species differences in development and organ structures. Additionally, despite the discovery of numerous molecular therapeutic strategies over recent decades, only a small fraction of drugs demonstrating preclinical efficacy have translated successfully into human clinical trials. This further underscores the need for innovative approaches to model tumorigenesis. Modeling early tumor development has become possible with the emergence of induced pluripotent stem cell (iPSC) technology, thereby opening new avenues for the discovery of potential therapeutic targets. This thesis describes the development of novel, disease-relevant model systems that integrate patient- derived iPSCs and zebrafish xenografts to faithfully recapitulate the early stages of MB tumorigenesis. The overall aim of this thesis was to develop both in vitro and in vivo models that mimic MB initiation and progression, thereby facilitating mechanistic studies and the identification of novel therapeutic targets.In Paper I, we established a new human model system for sonic hedgehog (SHH)- driven MB by utilizing neuroepithelial stem (NES) cells derived from non- cancerous Gorlin syndrome patient iPSCs. Re-transplantation of these cells leads to a more malignant phenotype and accelerated tumor formation, providing a robust platform for studying the molecular changes during tumor development. Importantly, this study identified LGALS1 (galectin-1) as a direct GLI target gene that is upregulated in SHH MB, recognizing it as a promising novel therapeutic target. Furthermore, we describe the development of an orthotopic zebrafish- based xenograft model for MB in Paper II. In this model, MB cells exhibited intrinsic homing to the hindbrain region of developing zebrafish embryos upon blastula- stage transplantation, a process further enhanced by in vitro neural stem cell culture conditions. The blastula-stage zebrafish xenografts not only recapitulated tumor growth and neurotropism across MB subgroups but also serve as an efficient in vivo system for rapid drug testing. This provides a scalable alternative to traditional mouse models. Both of these novel model systems have been used to elucidate the role of galectins in SHH-driven MB (Paper III). This study demonstrated that LGALS3 (galectin-3) is highly expressed in these tumors and plays a crucial role in maintaining primary cilia structures, thereby facilitating canonical SHH signaling. Functional studies revealed that loss or inhibition of galectin-3 reduces tumorigenicity by impairing cell proliferation, migration and overall tumor progression in vivo. Additionally, galectin-3 modulates amino acid uptake, particularly arginine, through a TGF-B-mediated transcriptional mechanism on the activity of its solute carrier (SLC) transporters. All of this highlights its potential as a therapeutic target for SHH-driven MB. Lastly, we present the development of a human in vitro iPSC-derived cerebellar organoid model to explore their potential as a model system for MB (Paper IV). These organoids, generated from both control and Gorlin syndrome patient-derived iPSCs, recapitulated critical aspects of cerebellar development. Notably, Gorlin- derived organoids displayed accelerated growth, increased proliferation, and a higher abundance of PAX6-positive cells compared to controls. This makes them an invaluable, all-human system for further exploration of MB pathogenesis.In conclusion, this thesis significantly advances MB research by developing innovative in vitro and in vivo models that more accurately mirror the early stages of MB tumor initiation and progression. Additionally, we demonstrate that these model systems enable the discovery of novel therapeutic targets for SHH-driven MB, holding promise for translational research.List of scientific papersI. Susanto E, Marin Navarro A, Zhou L, Sundström A, van Bree N, Stantic M, Moslem M, Tailor J, Rietdijk J, Zubillaga V, Hübner JM, Weishaupt H, Wolfsberger J, Alafuzoff I, Nordgren A, Magnaldo T, Siesjö P, Johnsen JI, Kool M, Tammimies K, Darabi A, Swartling FJ, Falk A, Wilhelm M. Modeling SHH-driven medulloblastoma with patient iPS cell-derived neural stem cells. Proc Natl Acad Sci U S A. 2020 Aug 18; 117(33) : 20127-20138. https://doi.org/10.1073/pnas.1920521117II. van Bree N, Oppelt AS, Lindstrom S, Zhou L, Boutin L, Coyle B, Swartling FJ, Johnsen JI, Brautigam L, Wilhelm M. Development of an orthotopic medulloblastoma zebrafish model for rapid drug testing. Neuro Oncol. 2025 Mar; 27(3) : 779-794. https://doi.org/10.1093/neuonc/noae210III. van Bree N, Oppelt AS, Zimmer E, Wiesinger ML, Kvastad L, Escudero Morlanes J, Marques R, Bell N, Boutin L, Dias J, Zetterberg F, Nilsson U, Schäfer S, Zhou L, Teixeira A, Wilhelm M. Galectin-3 supports tumorigenesis in SHH-driven medulloblastoma by coordinating ciliary signaling and amino acid transport. [Manuscript]IV. van Bree N, Haazen L, Falk A, Magnaldo T, Wilhelm M. Generation of Gorlin syndrome patient iPSC-derived cerebellum organoids as a model system for SHH-driven medulloblastoma. [Manuscript]
- 31 March 2025
- Published by Karolinska Institutet
Open AccessDevelopment of translational models and identification of novel therapeutic targets for medulloblastoma
Medulloblastoma (MB), the most frequent malignant brain cancer in children, has traditionally been studied using established cell lines, patient-derived xenografts, engineered mouse models, and orthotopic transplants. While these models have been instrumental in advancing our understanding of MB pathogenesis, they predominantly represent later stages of tumor development, failing to adequately capture the early events of tumor initiation and progression. Moreover, many preclinical in vivo models are unable to fully recapitulate human tumor pathogenesis due to species differences in development and organ structures. Additionally, despite the discovery of numerous molecular therapeutic strategies over recent decades, only a small fraction of drugs demonstrating preclinical efficacy have translated successfully into human clinical trials. This further underscores the need for innovative approaches to model tumorigenesis. Modeling early tumor development has become possible with the emergence of induced pluripotent stem cell (iPSC) technology, thereby opening new avenues for the discovery of potential therapeutic targets. This thesis describes the development of novel, disease-relevant model systems that integrate patient- derived iPSCs and zebrafish xenografts to faithfully recapitulate the early stages of MB tumorigenesis. The overall aim of this thesis was to develop both in vitro and in vivo models that mimic MB initiation and progression, thereby facilitating mechanistic studies and the identification of novel therapeutic targets.In Paper I, we established a new human model system for sonic hedgehog (SHH)- driven MB by utilizing neuroepithelial stem (NES) cells derived from non- cancerous Gorlin syndrome patient iPSCs. Re-transplantation of these cells leads to a more malignant phenotype and accelerated tumor formation, providing a robust platform for studying the molecular changes during tumor development. Importantly, this study identified LGALS1 (galectin-1) as a direct GLI target gene that is upregulated in SHH MB, recognizing it as a promising novel therapeutic target. Furthermore, we describe the development of an orthotopic zebrafish- based xenograft model for MB in Paper II. In this model, MB cells exhibited intrinsic homing to the hindbrain region of developing zebrafish embryos upon blastula- stage transplantation, a process further enhanced by in vitro neural stem cell culture conditions. The blastula-stage zebrafish xenografts not only recapitulated tumor growth and neurotropism across MB subgroups but also serve as an efficient in vivo system for rapid drug testing. This provides a scalable alternative to traditional mouse models. Both of these novel model systems have been used to elucidate the role of galectins in SHH-driven MB (Paper III). This study demonstrated that LGALS3 (galectin-3) is highly expressed in these tumors and plays a crucial role in maintaining primary cilia structures, thereby facilitating canonical SHH signaling. Functional studies revealed that loss or inhibition of galectin-3 reduces tumorigenicity by impairing cell proliferation, migration and overall tumor progression in vivo. Additionally, galectin-3 modulates amino acid uptake, particularly arginine, through a TGF-B-mediated transcriptional mechanism on the activity of its solute carrier (SLC) transporters. All of this highlights its potential as a therapeutic target for SHH-driven MB. Lastly, we present the development of a human in vitro iPSC-derived cerebellar organoid model to explore their potential as a model system for MB (Paper IV). These organoids, generated from both control and Gorlin syndrome patient-derived iPSCs, recapitulated critical aspects of cerebellar development. Notably, Gorlin- derived organoids displayed accelerated growth, increased proliferation, and a higher abundance of PAX6-positive cells compared to controls. This makes them an invaluable, all-human system for further exploration of MB pathogenesis.In conclusion, this thesis significantly advances MB research by developing innovative in vitro and in vivo models that more accurately mirror the early stages of MB tumor initiation and progression. Additionally, we demonstrate that these model systems enable the discovery of novel therapeutic targets for SHH-driven MB, holding promise for translational research.List of scientific papersI. Susanto E, Marin Navarro A, Zhou L, Sundström A, van Bree N, Stantic M, Moslem M, Tailor J, Rietdijk J, Zubillaga V, Hübner JM, Weishaupt H, Wolfsberger J, Alafuzoff I, Nordgren A, Magnaldo T, Siesjö P, Johnsen JI, Kool M, Tammimies K, Darabi A, Swartling FJ, Falk A, Wilhelm M. Modeling SHH-driven medulloblastoma with patient iPS cell-derived neural stem cells. Proc Natl Acad Sci U S A. 2020 Aug 18; 117(33) : 20127-20138. https://doi.org/10.1073/pnas.1920521117II. van Bree N, Oppelt AS, Lindstrom S, Zhou L, Boutin L, Coyle B, Swartling FJ, Johnsen JI, Brautigam L, Wilhelm M. Development of an orthotopic medulloblastoma zebrafish model for rapid drug testing. Neuro Oncol. 2025 Mar; 27(3) : 779-794. https://doi.org/10.1093/neuonc/noae210III. van Bree N, Oppelt AS, Zimmer E, Wiesinger ML, Kvastad L, Escudero Morlanes J, Marques R, Bell N, Boutin L, Dias J, Zetterberg F, Nilsson U, Schäfer S, Zhou L, Teixeira A, Wilhelm M. Galectin-3 supports tumorigenesis in SHH-driven medulloblastoma by coordinating ciliary signaling and amino acid transport. [Manuscript]IV. van Bree N, Haazen L, Falk A, Magnaldo T, Wilhelm M. Generation of Gorlin syndrome patient iPSC-derived cerebellum organoids as a model system for SHH-driven medulloblastoma. [Manuscript]
- Open Access
- 31 March 2025
- Published by Karolinska Institutet
Development of translational models and identification of novel therapeutic targets for medulloblastoma
Medulloblastoma (MB), the most frequent malignant brain cancer in children, has traditionally been studied using established cell lines, patient-derived xenografts, engineered mouse models, and orthotopic transplants. While these models have been instrumental in advancing our understanding of MB pathogenesis, they predominantly represent later stages of tumor development, failing to adequately capture the early events of tumor initiation and progression. Moreover, many preclinical in vivo models are unable to fully recapitulate human tumor pathogenesis due to species differences in development and organ structures. Additionally, despite the discovery of numerous molecular therapeutic strategies over recent decades, only a small fraction of drugs demonstrating preclinical efficacy have translated successfully into human clinical trials. This further underscores the need for innovative approaches to model tumorigenesis. Modeling early tumor development has become possible with the emergence of induced pluripotent stem cell (iPSC) technology, thereby opening new avenues for the discovery of potential therapeutic targets. This thesis describes the development of novel, disease-relevant model systems that integrate patient- derived iPSCs and zebrafish xenografts to faithfully recapitulate the early stages of MB tumorigenesis. The overall aim of this thesis was to develop both in vitro and in vivo models that mimic MB initiation and progression, thereby facilitating mechanistic studies and the identification of novel therapeutic targets.In Paper I, we established a new human model system for sonic hedgehog (SHH)- driven MB by utilizing neuroepithelial stem (NES) cells derived from non- cancerous Gorlin syndrome patient iPSCs. Re-transplantation of these cells leads to a more malignant phenotype and accelerated tumor formation, providing a robust platform for studying the molecular changes during tumor development. Importantly, this study identified LGALS1 (galectin-1) as a direct GLI target gene that is upregulated in SHH MB, recognizing it as a promising novel therapeutic target. Furthermore, we describe the development of an orthotopic zebrafish- based xenograft model for MB in Paper II. In this model, MB cells exhibited intrinsic homing to the hindbrain region of developing zebrafish embryos upon blastula- stage transplantation, a process further enhanced by in vitro neural stem cell culture conditions. The blastula-stage zebrafish xenografts not only recapitulated tumor growth and neurotropism across MB subgroups but also serve as an efficient in vivo system for rapid drug testing. This provides a scalable alternative to traditional mouse models. Both of these novel model systems have been used to elucidate the role of galectins in SHH-driven MB (Paper III). This study demonstrated that LGALS3 (galectin-3) is highly expressed in these tumors and plays a crucial role in maintaining primary cilia structures, thereby facilitating canonical SHH signaling. Functional studies revealed that loss or inhibition of galectin-3 reduces tumorigenicity by impairing cell proliferation, migration and overall tumor progression in vivo. Additionally, galectin-3 modulates amino acid uptake, particularly arginine, through a TGF-B-mediated transcriptional mechanism on the activity of its solute carrier (SLC) transporters. All of this highlights its potential as a therapeutic target for SHH-driven MB. Lastly, we present the development of a human in vitro iPSC-derived cerebellar organoid model to explore their potential as a model system for MB (Paper IV). These organoids, generated from both control and Gorlin syndrome patient-derived iPSCs, recapitulated critical aspects of cerebellar development. Notably, Gorlin- derived organoids displayed accelerated growth, increased proliferation, and a higher abundance of PAX6-positive cells compared to controls. This makes them an invaluable, all-human system for further exploration of MB pathogenesis.In conclusion, this thesis significantly advances MB research by developing innovative in vitro and in vivo models that more accurately mirror the early stages of MB tumor initiation and progression. Additionally, we demonstrate that these model systems enable the discovery of novel therapeutic targets for SHH-driven MB, holding promise for translational research.List of scientific papersI. Susanto E, Marin Navarro A, Zhou L, Sundström A, van Bree N, Stantic M, Moslem M, Tailor J, Rietdijk J, Zubillaga V, Hübner JM, Weishaupt H, Wolfsberger J, Alafuzoff I, Nordgren A, Magnaldo T, Siesjö P, Johnsen JI, Kool M, Tammimies K, Darabi A, Swartling FJ, Falk A, Wilhelm M. Modeling SHH-driven medulloblastoma with patient iPS cell-derived neural stem cells. Proc Natl Acad Sci U S A. 2020 Aug 18; 117(33) : 20127-20138. https://doi.org/10.1073/pnas.1920521117II. van Bree N, Oppelt AS, Lindstrom S, Zhou L, Boutin L, Coyle B, Swartling FJ, Johnsen JI, Brautigam L, Wilhelm M. Development of an orthotopic medulloblastoma zebrafish model for rapid drug testing. Neuro Oncol. 2025 Mar; 27(3) : 779-794. https://doi.org/10.1093/neuonc/noae210III. van Bree N, Oppelt AS, Zimmer E, Wiesinger ML, Kvastad L, Escudero Morlanes J, Marques R, Bell N, Boutin L, Dias J, Zetterberg F, Nilsson U, Schäfer S, Zhou L, Teixeira A, Wilhelm M. Galectin-3 supports tumorigenesis in SHH-driven medulloblastoma by coordinating ciliary signaling and amino acid transport. [Manuscript]IV. van Bree N, Haazen L, Falk A, Magnaldo T, Wilhelm M. Generation of Gorlin syndrome patient iPSC-derived cerebellum organoids as a model system for SHH-driven medulloblastoma. [Manuscript]
- 31 March 2025
- Published by Karolinska Institutet
Open AccessDevelopment of translational models and identification of novel therapeutic targets for medulloblastoma
Medulloblastoma (MB), the most frequent malignant brain cancer in children, has traditionally been studied using established cell lines, patient-derived xenografts, engineered mouse models, and orthotopic transplants. While these models have been instrumental in advancing our understanding of MB pathogenesis, they predominantly represent later stages of tumor development, failing to adequately capture the early events of tumor initiation and progression. Moreover, many preclinical in vivo models are unable to fully recapitulate human tumor pathogenesis due to species differences in development and organ structures. Additionally, despite the discovery of numerous molecular therapeutic strategies over recent decades, only a small fraction of drugs demonstrating preclinical efficacy have translated successfully into human clinical trials. This further underscores the need for innovative approaches to model tumorigenesis. Modeling early tumor development has become possible with the emergence of induced pluripotent stem cell (iPSC) technology, thereby opening new avenues for the discovery of potential therapeutic targets. This thesis describes the development of novel, disease-relevant model systems that integrate patient- derived iPSCs and zebrafish xenografts to faithfully recapitulate the early stages of MB tumorigenesis. The overall aim of this thesis was to develop both in vitro and in vivo models that mimic MB initiation and progression, thereby facilitating mechanistic studies and the identification of novel therapeutic targets.In Paper I, we established a new human model system for sonic hedgehog (SHH)- driven MB by utilizing neuroepithelial stem (NES) cells derived from non- cancerous Gorlin syndrome patient iPSCs. Re-transplantation of these cells leads to a more malignant phenotype and accelerated tumor formation, providing a robust platform for studying the molecular changes during tumor development. Importantly, this study identified LGALS1 (galectin-1) as a direct GLI target gene that is upregulated in SHH MB, recognizing it as a promising novel therapeutic target. Furthermore, we describe the development of an orthotopic zebrafish- based xenograft model for MB in Paper II. In this model, MB cells exhibited intrinsic homing to the hindbrain region of developing zebrafish embryos upon blastula- stage transplantation, a process further enhanced by in vitro neural stem cell culture conditions. The blastula-stage zebrafish xenografts not only recapitulated tumor growth and neurotropism across MB subgroups but also serve as an efficient in vivo system for rapid drug testing. This provides a scalable alternative to traditional mouse models. Both of these novel model systems have been used to elucidate the role of galectins in SHH-driven MB (Paper III). This study demonstrated that LGALS3 (galectin-3) is highly expressed in these tumors and plays a crucial role in maintaining primary cilia structures, thereby facilitating canonical SHH signaling. Functional studies revealed that loss or inhibition of galectin-3 reduces tumorigenicity by impairing cell proliferation, migration and overall tumor progression in vivo. Additionally, galectin-3 modulates amino acid uptake, particularly arginine, through a TGF-B-mediated transcriptional mechanism on the activity of its solute carrier (SLC) transporters. All of this highlights its potential as a therapeutic target for SHH-driven MB. Lastly, we present the development of a human in vitro iPSC-derived cerebellar organoid model to explore their potential as a model system for MB (Paper IV). These organoids, generated from both control and Gorlin syndrome patient-derived iPSCs, recapitulated critical aspects of cerebellar development. Notably, Gorlin- derived organoids displayed accelerated growth, increased proliferation, and a higher abundance of PAX6-positive cells compared to controls. This makes them an invaluable, all-human system for further exploration of MB pathogenesis.In conclusion, this thesis significantly advances MB research by developing innovative in vitro and in vivo models that more accurately mirror the early stages of MB tumor initiation and progression. Additionally, we demonstrate that these model systems enable the discovery of novel therapeutic targets for SHH-driven MB, holding promise for translational research.List of scientific papersI. Susanto E, Marin Navarro A, Zhou L, Sundström A, van Bree N, Stantic M, Moslem M, Tailor J, Rietdijk J, Zubillaga V, Hübner JM, Weishaupt H, Wolfsberger J, Alafuzoff I, Nordgren A, Magnaldo T, Siesjö P, Johnsen JI, Kool M, Tammimies K, Darabi A, Swartling FJ, Falk A, Wilhelm M. Modeling SHH-driven medulloblastoma with patient iPS cell-derived neural stem cells. Proc Natl Acad Sci U S A. 2020 Aug 18; 117(33) : 20127-20138. https://doi.org/10.1073/pnas.1920521117II. van Bree N, Oppelt AS, Lindstrom S, Zhou L, Boutin L, Coyle B, Swartling FJ, Johnsen JI, Brautigam L, Wilhelm M. Development of an orthotopic medulloblastoma zebrafish model for rapid drug testing. Neuro Oncol. 2025 Mar; 27(3) : 779-794. https://doi.org/10.1093/neuonc/noae210III. van Bree N, Oppelt AS, Zimmer E, Wiesinger ML, Kvastad L, Escudero Morlanes J, Marques R, Bell N, Boutin L, Dias J, Zetterberg F, Nilsson U, Schäfer S, Zhou L, Teixeira A, Wilhelm M. Galectin-3 supports tumorigenesis in SHH-driven medulloblastoma by coordinating ciliary signaling and amino acid transport. [Manuscript]IV. van Bree N, Haazen L, Falk A, Magnaldo T, Wilhelm M. Generation of Gorlin syndrome patient iPSC-derived cerebellum organoids as a model system for SHH-driven medulloblastoma. [Manuscript]
- Open Access
- 9 October 2024
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 27 (3) , 779-794
Development of an orthotopic medulloblastoma zebrafish model for rapid drug testing
Medulloblastoma (MB) is one of the most common malignant brain tumors in children. Current preclinical in vivo model systems for MB have increased our understanding of molecular mechanisms regulating MB development. However, they may not be suitable for large-scale studies. The aim of this study was to investigate if a zebrafish-based xenograft model can recapitulate MB growth and enable rapid drug testing. Nine different MB cell lines or patient-derived cells were transplanted into blastula-stage zebrafish embryos. Tumor development and migration were then monitored using live imaging. RNA sequencing was performed to investigate transcriptome changes after conditioning cells in neural stem cell-like medium. Furthermore, drug treatments were tested in a 96-well format. We demonstrate here that transplantation of MB cells into the blastula stage of zebrafish embryos leads to orthotopic tumor growth that can be observed within 24 hours after transplantation. Importantly, the homing of transplanted cells to the hindbrain region and the aggressiveness of tumor growth are enhanced by pre-culturing cells in a neural stem cell-like medium. The change in culture conditions rewires the transcriptome towards a more migratory and neuronal phenotype, including the expression of guidance molecules SEMA3A and EFNB1, both of which correlate with lower overall survival in MB patients. Furthermore, we highlight that the orthotopic zebrafish MB model has the potential to be used for rapid drug testing. Blastula-stage zebrafish MB xenografts present an alternative to current MB mouse xenograft models, enabling quick evaluation of tumor cell growth, neurotropism, and drug efficacy.
- 9 October 2024
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 27 (3) , 779-794
Open AccessDevelopment of an orthotopic medulloblastoma zebrafish model for rapid drug testing
Medulloblastoma (MB) is one of the most common malignant brain tumors in children. Current preclinical in vivo model systems for MB have increased our understanding of molecular mechanisms regulating MB development. However, they may not be suitable for large-scale studies. The aim of this study was to investigate if a zebrafish-based xenograft model can recapitulate MB growth and enable rapid drug testing. Nine different MB cell lines or patient-derived cells were transplanted into blastula-stage zebrafish embryos. Tumor development and migration were then monitored using live imaging. RNA sequencing was performed to investigate transcriptome changes after conditioning cells in neural stem cell-like medium. Furthermore, drug treatments were tested in a 96-well format. We demonstrate here that transplantation of MB cells into the blastula stage of zebrafish embryos leads to orthotopic tumor growth that can be observed within 24 hours after transplantation. Importantly, the homing of transplanted cells to the hindbrain region and the aggressiveness of tumor growth are enhanced by pre-culturing cells in a neural stem cell-like medium. The change in culture conditions rewires the transcriptome towards a more migratory and neuronal phenotype, including the expression of guidance molecules SEMA3A and EFNB1, both of which correlate with lower overall survival in MB patients. Furthermore, we highlight that the orthotopic zebrafish MB model has the potential to be used for rapid drug testing. Blastula-stage zebrafish MB xenografts present an alternative to current MB mouse xenograft models, enabling quick evaluation of tumor cell growth, neurotropism, and drug efficacy.
- Open Access
The Tumor Microenvironment of Medulloblastoma: An Intricate Multicellular Network with Therapeutic Potential
Medulloblastoma (MB) is a heterogeneous disease in which survival is highly affected by the underlying subgroup-specific characteristics. Although the current treatment modalities have increased the overall survival rates of MB up to 70–80%, MB remains a major cause of cancer-related mortality among children. This indicates that novel therapeutic approaches against MB are needed. New promising treatment options comprise the targeting of cells and components of the tumor microenvironment (TME). The TME of MB consists of an intricate multicellular network of tumor cells, progenitor cells, astrocytes, neurons, supporting stromal cells, microglia, immune cells, extracellular matrix components, and vasculature systems. In this review, we will discuss all the different components of the MB TME and their role in MB initiation, progression, metastasis, and relapse. Additionally, we briefly introduce the effect that age plays on the TME of brain malignancies and discuss the MB subgroup-specific differences in TME components and how all of these variations could affect the progression of MB. Finally, we highlight the TME-directed treatments, in which we will focus on therapies that are being evaluated in clinical trials.
Open AccessThe Tumor Microenvironment of Medulloblastoma: An Intricate Multicellular Network with Therapeutic Potential
Medulloblastoma (MB) is a heterogeneous disease in which survival is highly affected by the underlying subgroup-specific characteristics. Although the current treatment modalities have increased the overall survival rates of MB up to 70–80%, MB remains a major cause of cancer-related mortality among children. This indicates that novel therapeutic approaches against MB are needed. New promising treatment options comprise the targeting of cells and components of the tumor microenvironment (TME). The TME of MB consists of an intricate multicellular network of tumor cells, progenitor cells, astrocytes, neurons, supporting stromal cells, microglia, immune cells, extracellular matrix components, and vasculature systems. In this review, we will discuss all the different components of the MB TME and their role in MB initiation, progression, metastasis, and relapse. Additionally, we briefly introduce the effect that age plays on the TME of brain malignancies and discuss the MB subgroup-specific differences in TME components and how all of these variations could affect the progression of MB. Finally, we highlight the TME-directed treatments, in which we will focus on therapies that are being evaluated in clinical trials.
- Open Access
- 9 March 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (10)
TAp73 represses NF-κB–mediated recruitment of tumor-associated macrophages in breast cancer
Infiltration of tumor-promoting immune cells is a strong driver of tumor progression. Especially the accumulation of macrophages in the tumor microenvironment is known to facilitate tumor growth and to correlate with poor prognosis in many tumor types. TAp73, a member of the p53/p63/p73 family, acts as a tumor suppressor and has been shown to suppress tumor angiogenesis. However, what role TAp73 has in regulating immune cell infiltration is unknown. Here, we report that low levels of TAp73 correlate with an increased NF-κB–regulated inflammatory signature in breast cancer. Furthermore, we show that loss of TAp73 results in NF-κB hyperactivation and secretion of Ccl2, a known NF-κB target and chemoattractant for monocytes and macrophages. Importantly, TAp73-deficient tumors display an increased accumulation of protumoral macrophages that express the mannose receptor (CD206) and scavenger receptor A (CD204) compared to controls. The relevance of TAp73 expression in human breast carcinoma was further accentuated by revealing that TAp73 expression correlates negatively with the accumulation of protumoral CD163+ macrophages in breast cancer patient samples. Taken together, our findings suggest that TAp73 regulates macrophage accumulation and phenotype in breast cancer through inhibition of the NF-κB pathway. Significance Breast cancer is one of the most prevalent cancers worldwide. Understanding this complex disease is therefore of great importance. Here, we report that loss of TAp73, a known tumor suppressor and member of the p53 protein family, leads to increased activation of the NF-κB pathway, secretion of the chemokine CCL2, and an increase in protumoral macrophage infiltration in human breast cancer. Both high levels of CCL2 and high macrophage infiltration are known to correlate with poor prognosis in breast cancer patients. This study identifies TAp73 as a regulator of macrophage recruitment and highlights a role for TAp73 in immune cell regulation in cancer.
- 9 March 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (10)
Open AccessTAp73 represses NF-κB–mediated recruitment of tumor-associated macrophages in breast cancer
Infiltration of tumor-promoting immune cells is a strong driver of tumor progression. Especially the accumulation of macrophages in the tumor microenvironment is known to facilitate tumor growth and to correlate with poor prognosis in many tumor types. TAp73, a member of the p53/p63/p73 family, acts as a tumor suppressor and has been shown to suppress tumor angiogenesis. However, what role TAp73 has in regulating immune cell infiltration is unknown. Here, we report that low levels of TAp73 correlate with an increased NF-κB–regulated inflammatory signature in breast cancer. Furthermore, we show that loss of TAp73 results in NF-κB hyperactivation and secretion of Ccl2, a known NF-κB target and chemoattractant for monocytes and macrophages. Importantly, TAp73-deficient tumors display an increased accumulation of protumoral macrophages that express the mannose receptor (CD206) and scavenger receptor A (CD204) compared to controls. The relevance of TAp73 expression in human breast carcinoma was further accentuated by revealing that TAp73 expression correlates negatively with the accumulation of protumoral CD163+ macrophages in breast cancer patient samples. Taken together, our findings suggest that TAp73 regulates macrophage accumulation and phenotype in breast cancer through inhibition of the NF-κB pathway. Significance Breast cancer is one of the most prevalent cancers worldwide. Understanding this complex disease is therefore of great importance. Here, we report that loss of TAp73, a known tumor suppressor and member of the p53 protein family, leads to increased activation of the NF-κB pathway, secretion of the chemokine CCL2, and an increase in protumoral macrophage infiltration in human breast cancer. Both high levels of CCL2 and high macrophage infiltration are known to correlate with poor prognosis in breast cancer patients. This study identifies TAp73 as a regulator of macrophage recruitment and highlights a role for TAp73 in immune cell regulation in cancer.
- Open Access
- 3 August 2020
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 117 (33) , 20127-20138
Modeling SHH-driven medulloblastoma with patient iPS cell-derived neural stem cells
Medulloblastoma is the most common malignant brain tumor in children. Here we describe a medulloblastoma model using Induced pluripotent stem (iPS) cell-derived human neuroepithelial stem (NES) cells generated from a Gorlin syndrome patient carrying a germline mutation in the sonic hedgehog (SHH) receptor PTCH1. We found that Gorlin NES cells formed tumors in mouse cerebellum mimicking human medulloblastoma. Retransplantation of tumor-isolated NES (tNES) cells resulted in accelerated tumor formation, cells with reduced growth factor dependency, enhanced neurosphere formation in vitro, and increased sensitivity to Vismodegib. Using our model, we identified LGALS1 to be a GLI target gene that is up-regulated in both Gorlin tNES cells and SHH-subgroup of medulloblastoma patients. Taken together, we demonstrate that NES cells derived from Gorlin patients can be used as a resource to model medulloblastoma initiation and progression and to identify putative targets. Significance Here we describe and utilize a model of medulloblastoma, a malignancy accounting for 20% of all childhood brain cancers. We used iPS-derived neural stem cells with a familial mutation causing aberrant SHH signaling. We show that these cells, when transplanted into mouse cerebellum, form tumors that mimics SHH-driven medulloblastoma, demonstrating the development of cancer from healthy neural stem cells in vivo. Our results show that reprogramming of somatic cells carrying familial cancer mutations can be used to model the initiation and progression of childhood cancer.
- 3 August 2020
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 117 (33) , 20127-20138
Open AccessModeling SHH-driven medulloblastoma with patient iPS cell-derived neural stem cells
Medulloblastoma is the most common malignant brain tumor in children. Here we describe a medulloblastoma model using Induced pluripotent stem (iPS) cell-derived human neuroepithelial stem (NES) cells generated from a Gorlin syndrome patient carrying a germline mutation in the sonic hedgehog (SHH) receptor PTCH1. We found that Gorlin NES cells formed tumors in mouse cerebellum mimicking human medulloblastoma. Retransplantation of tumor-isolated NES (tNES) cells resulted in accelerated tumor formation, cells with reduced growth factor dependency, enhanced neurosphere formation in vitro, and increased sensitivity to Vismodegib. Using our model, we identified LGALS1 to be a GLI target gene that is up-regulated in both Gorlin tNES cells and SHH-subgroup of medulloblastoma patients. Taken together, we demonstrate that NES cells derived from Gorlin patients can be used as a resource to model medulloblastoma initiation and progression and to identify putative targets. Significance Here we describe and utilize a model of medulloblastoma, a malignancy accounting for 20% of all childhood brain cancers. We used iPS-derived neural stem cells with a familial mutation causing aberrant SHH signaling. We show that these cells, when transplanted into mouse cerebellum, form tumors that mimics SHH-driven medulloblastoma, demonstrating the development of cancer from healthy neural stem cells in vivo. Our results show that reprogramming of somatic cells carrying familial cancer mutations can be used to model the initiation and progression of childhood cancer.
- Open Access
- 11 April 2020
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 146 (7) , 1659-1670
Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo
Purpose: Desmoplastic small round cell tumors (DSRCTs) are highly malignant and very rare soft tissue sarcomas with a high unmet need for new therapeutic options. Therefore, we examined poly(ADP-ribose) polymerase 1 (PARP1) and Schlafen-11 (SLFN11) expression in DSRCT tumor tissue and the combination of PARP inhibitor olaparib with the alkylating agent temozolomide (TMZ) in a preclinical DSRCT model. Methods: PARP1 and SLFN11 have been described as predictive biomarkers for response to PARP inhibition. Expression of PARP1 and SLFN11 was assessed in 16 and 12 DSRCT tumor tissue samples, respectively. Effects of single-agent olaparib, and olaparib and TMZ combination treatment were examined using the preclinical JN-DSRCT-1 model. In vitro, single-agent and combination treatment effects on cell viability, the cell cycle, DNA damage and apoptosis were examined. Olaparib and TMZ combination treatment was also assessed in vivo. Results: PARP1 and SLFN11 expression was observed in 100% and 92% of DSRCT tumor tissues, respectively. Olaparib treatment reduced cell viability and cell migration in a dose-dependent manner in vitro. Drug synergy between olaparib and TMZ was observed in vitro and in vivo. Combination treatment led to a cell-cycle arrest and induction of DNA damage and apoptosis, even when combined at low dosages. Conclusion: We show high PARP1 and SLFN11 expression in DSRCT tumor material and antitumor effects following olaparib and TMZ combination treatment in a preclinical DSRCT model. This suggests that olaparib and TMZ combination treatment could be a potential treatment option for DSRCTs.
- 11 April 2020
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 146 (7) , 1659-1670
Open AccessOlaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo
Purpose: Desmoplastic small round cell tumors (DSRCTs) are highly malignant and very rare soft tissue sarcomas with a high unmet need for new therapeutic options. Therefore, we examined poly(ADP-ribose) polymerase 1 (PARP1) and Schlafen-11 (SLFN11) expression in DSRCT tumor tissue and the combination of PARP inhibitor olaparib with the alkylating agent temozolomide (TMZ) in a preclinical DSRCT model. Methods: PARP1 and SLFN11 have been described as predictive biomarkers for response to PARP inhibition. Expression of PARP1 and SLFN11 was assessed in 16 and 12 DSRCT tumor tissue samples, respectively. Effects of single-agent olaparib, and olaparib and TMZ combination treatment were examined using the preclinical JN-DSRCT-1 model. In vitro, single-agent and combination treatment effects on cell viability, the cell cycle, DNA damage and apoptosis were examined. Olaparib and TMZ combination treatment was also assessed in vivo. Results: PARP1 and SLFN11 expression was observed in 100% and 92% of DSRCT tumor tissues, respectively. Olaparib treatment reduced cell viability and cell migration in a dose-dependent manner in vitro. Drug synergy between olaparib and TMZ was observed in vitro and in vivo. Combination treatment led to a cell-cycle arrest and induction of DNA damage and apoptosis, even when combined at low dosages. Conclusion: We show high PARP1 and SLFN11 expression in DSRCT tumor material and antitumor effects following olaparib and TMZ combination treatment in a preclinical DSRCT model. This suggests that olaparib and TMZ combination treatment could be a potential treatment option for DSRCTs.
- Open Access
- 8 June 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 3086
Leukocyte Bim deficiency does not impact atherogenesis in ldlr −/− mice, despite a pronounced induction of autoimmune inflammation
Proapoptotic Bcl-2 family member Bim is particularly relevant for deletion of autoreactive and activated T and B cells, implicating Bim in autoimmunity. As atherosclerosis is a chronic inflammatory process with features of autoimmune disease, we investigated the impact of hematopoietic Bim deficiency on plaque formation and parameters of plaque stability. Bim−/− or wild type bone marrow transplanted ldlr−/− mice were fed a Western type diet (WTD) for 5 or 10 weeks, after which they were immunophenotyped and atherosclerotic lesions were analyzed. Bim−/− transplanted mice displayed splenomegaly and overt lymphocytosis. CD4+ and CD8+ T cells were more activated (increased CD69 and CD71 expression, increased interferon gamma production). B cells were elevated by 147%, with a shift towards the pro-atherogenic IgG-producing B2 cell phenotype, resulting in a doubling of anti-oxLDL IgG1 antibody titers in serum of bim−/− mice. Bim−/− mice displayed massive intraplaque accumulation of Ig complexes and of lesional T cells, although this did not translate in changes in plaque size or stability features (apoptotic cell and macrophage content). The surprising lack in plaque phenotype despite the profound pro-atherogenic immune effects may be attributable to the sharp reduction of serum cholesterol levels in WTD fed bim−/− mice.
- 8 June 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 3086
Open AccessLeukocyte Bim deficiency does not impact atherogenesis in ldlr −/− mice, despite a pronounced induction of autoimmune inflammation
Proapoptotic Bcl-2 family member Bim is particularly relevant for deletion of autoreactive and activated T and B cells, implicating Bim in autoimmunity. As atherosclerosis is a chronic inflammatory process with features of autoimmune disease, we investigated the impact of hematopoietic Bim deficiency on plaque formation and parameters of plaque stability. Bim−/− or wild type bone marrow transplanted ldlr−/− mice were fed a Western type diet (WTD) for 5 or 10 weeks, after which they were immunophenotyped and atherosclerotic lesions were analyzed. Bim−/− transplanted mice displayed splenomegaly and overt lymphocytosis. CD4+ and CD8+ T cells were more activated (increased CD69 and CD71 expression, increased interferon gamma production). B cells were elevated by 147%, with a shift towards the pro-atherogenic IgG-producing B2 cell phenotype, resulting in a doubling of anti-oxLDL IgG1 antibody titers in serum of bim−/− mice. Bim−/− mice displayed massive intraplaque accumulation of Ig complexes and of lesional T cells, although this did not translate in changes in plaque size or stability features (apoptotic cell and macrophage content). The surprising lack in plaque phenotype despite the profound pro-atherogenic immune effects may be attributable to the sharp reduction of serum cholesterol levels in WTD fed bim−/− mice.